ABV-1702

N/A

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameABV-1702
Drug Alias NameABV-1702BLEX-404BLI-1401ABV-1501ABV-1703 +[7] 
ClassificationSmall molecules > Heterocyclic drugsNatural product/Extract > Microbial extract
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiolite Inc
China Registration ClassN/A

Develop Information

Active CompaniesRgene CoOncoX BioPharma IncAbvc BioPharma Inc +[4] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A